Fineline Cube

Follow:
14422 Articles
Fosun Pharma Secures China Rights to Accropeutics’ AC‑201 JAK Inhibitor
CompanyDeals

Fosun Pharma Secures China Rights to Accropeutics’ AC‑201 JAK Inhibitor

Shenlian Bio Launches Phase 2 Trial for UB‑221 Injection in Chronic Urticaria
CompanyDrug

Shenlian Bio Launches Phase 2 Trial for UB‑221 Injection in Chronic Urticaria

Mabwell’s 9MW3811 Receives NMPA Phase II Approval for Pathological Scar Treatment
CompanyDrug

Mabwell’s 9MW3811 Receives NMPA Phase II Approval for Pathological Scar Treatment

Suzhou Zelgen Secures FDA Approval for Dual‑Targeted Therapy Trial in Advanced Solid Tumors
CompanyDrug

Suzhou Zelgen Secures FDA Approval for Dual‑Targeted Therapy Trial in Advanced Solid Tumors

Mabwell Secures First Overseas Approval for Denosumab Biosimilars in Pakistan
CompanyDrug

Mabwell Secures First Overseas Approval for Denosumab Biosimilars in Pakistan

Novo Nordisk’s STEER Study: Wegovy Cuts Cardiovascular Risk 57 % vs. Tirzepatide
CompanyDrug

Novo Nordisk’s STEER Study: Wegovy Cuts Cardiovascular Risk 57 % vs. Tirzepatide

Eisai & Biogen Secure FDA Approval for Lecanemab Auto‑Injector – Home‑Based Alzheimer’s Therapy
CompanyDrug

Eisai & Biogen Secure FDA Approval for Lecanemab Auto‑Injector – Home‑Based Alzheimer’s Therapy

PackGene & CMRI Announce AAV Screening Kit for Global Gene Therapy R&D
CompanyDeals

PackGene & CMRI Announce AAV Screening Kit for Global Gene Therapy R&D

Suzhou HemaCell Receives NMPA IND Approval for First‑In‑Class Megakaryocyte Injection – Thrombocytopenia Treatment
CompanyDrug

Suzhou HemaCell Receives NMPA IND Approval for First‑In‑Class Megakaryocyte Injection – Thrombocytopenia Treatment

Everest Medicines Reports 48 % YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone
Company

Everest Medicines Reports 48 % YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone

Luye Pharma Reports 1H 2025 Revenue Growth of 3.5 % Amid Oncology and CNS Gains
Company

Luye Pharma Reports 1H 2025 Revenue Growth of 3.5 % Amid Oncology and CNS Gains

Shanghai Pharma Reports 2025 Interim Results: 1.6% Revenue Rise, 41% Profit Surge
Company

Shanghai Pharma Reports 2025 Interim Results: 1.6% Revenue Rise, 41% Profit Surge